NIQ Launches Survey Groups to Connect Consumer Sentiment with Real Purchase Behavior
27.5.2026 13:00:00 CEST | Business Wire | Press Release
NIQ (NYSE: NIQ), a global leader in consumer intelligence, today announced the launch of Survey Groups in NIQ Discover, a new capability that enables brands and retailers to understand not just what is changing in the market, but why.
Available immediately within NIQ Discover, Survey Groups build on NIQ Panel Surveys by linking attitudinal insights to real-world purchase behavior from NIQ’s consumer panels—helping clients uncover the motivations behind performance shifts, identify opportunity gaps, and act with greater confidence in an increasingly complex consumer landscape.
What’s New: Survey Groups in Discover
Survey Groups make NIQ Panel Survey insights easier to access, analyze, and activate within existing workflows. By grouping survey responses with purchase behavior, clients can:
- Analyze key consumer segments with greater precision
- Understand the drivers behind brand and category performance
- Identify barriers to purchase and causes of brand or category lapsing
- Surface emerging growth opportunities rooted in real behavior
- Create self-serve analyses directly within Discover
Why It Matters: Moving Beyond Claimed Behavior
As consumer decision‑making becomes more fragmented and unpredictable, traditional surveys often based solely on claimed behavior can fall short of explaining real‑world outcomes. Survey Groups address this gap by tying what consumers say directly to what they do. This integration allows businesses to move beyond surface‑level insights and gain a deeper, more reliable understanding of motivations, helping teams prioritize actions that inform growth strategies.
“NIQ has delivered Panel Survey capabilities for many years, helping clients understand the motivations behind consumer behavior through verified purchase data,” said Troy Treangen, Chief Product Officer at NIQ. “What’s new with Survey Groups is that these insights are now integrated directly into Discover, making them easier to access, analyze, and activate within existing workflows. By bringing survey insights and consumer behavior together in one platform, clients can move faster from insight to action with a more connected view of performance.”
How It Works: Sentiment Meets Verified Purchase Data
Survey Groups are powered by NIQ Panel Surveys, which are directly connected to NIQ’s robust consumer panels in the FMCG industry. This linkage provides a more representative view of consumer behavior, grounding insights in transactional purchase data rather than intention alone.
Within NIQ Discover, the same surveyable population can be analyzed while maintaining consistent sample coverage as Survey Groups are activated for deeper analysis. Teams can independently create and analyze Survey Groups at the question-and answer-level, enabling self-serve segmentation across markets. By bringing these insights into Discover, NIQ enables faster analysis, easier collaboration, and more confident decision‑making across teams.
What’s Next: Continued Investment in Panel Surveys
Survey Groups represent the first step in a broader roadmap for NIQ Panel Surveys. NIQ will continue to invest in making these insights more accessible, actionable, and deeply integrated within Discover, with additional enhancements planned throughout 2026 and beyond.
These advancements support NIQ’s broader strategy to unify measurement, panel, and survey insights within a single platform enabling faster, clearer, and more confident decision‑making for clients worldwide.
As consumer behavior grows more complex, the ability to connect motivations to outcomes is becoming a critical advantage. By integrating survey sentiment with real-world purchase behavior, Survey Groups help brands and retailers turn insight into action—closing gaps between understanding and execution, and enabling more informed, confident decision-making.
In a market where knowing why matters as much as knowing what, NIQ is redefining how consumer intelligence powers performance. For more information visit NIQ Discover.
Frequently Asked Questions:
Q: What are NIQ Survey Groups?
A: Survey Groups are a new capability within NIQ Discover that connect consumer survey responses directly to real-world purchase behavior from NIQ’s consumer panels, enabling deeper insight into the motivations behind market performance.
Q: How are NIQ Survey Groups different from traditional surveys?
A: Traditional surveys rely on claimed or self‑reported behavior, which can differ from actual actions. Survey Groups link what consumers say with what they actually buy, providing a more accurate view of consumer decision‑making.
Q: Who can benefit from Survey Groups?
A: Survey Groups are designed for brands, retailers, and manufacturers looking to understand the drivers behind brand and category performance, identify growth opportunities, reduce churn or lapsing, and make more confident, data‑driven decisions.
Q: Where are Survey Groups available?
A: Survey Groups are available directly within NIQ Discover, allowing clients to access, analyze, and apply these insights within their existing workflows.
Q: What types of insights do Survey Groups deliver?
A: Survey Groups help uncover key consumer segments, drivers of brand and category growth or decline, barriers to purchase, reasons for lapsing, and emerging opportunities—grounded in real purchasing behavior.
Q: How do Survey Groups support faster decision‑making?
A: By integrating survey, panel, and measurement data in a single platform, Survey Groups make insights easier to access and apply, reducing time to insight and enabling teams to move from analysis to action more quickly.
Q: Is this a standalone launch or part of a broader roadmap?
A: Survey Groups represent the first step in a broader set of enhancements to NIQ Panel Surveys. NIQ will continue to invest in expanding and improving these capabilities throughout 2026 and beyond.
Q: How does this fit into NIQ’s overall strategy?
A: Survey Groups support NIQ’s mission to deliver the Full View™ of consumer behavior by connecting measurement, panel, and survey insights in a single, integrated platform—helping clients navigate increasingly complex consumer ecosystems with confidence.
About NIQ
NielsenIQ (NYSE: NIQ) is a leading consumer intelligence company, delivering the most complete and trusted understanding of consumer buying behavior and revealing the pathways to growth. By combining an unmatched global data footprint and granular consumer and retail measurement with decades of AI modeling expertise, NIQ builds decision systems that help companies turn complex data into confident action.
With operations in more than 90 countries, NIQ covers approximately 82% of the world’s population and more than $7.4 trillion in global consumer spend. Through cloud-based platforms, advanced analytics and AI-driven insights, NIQ delivers The Full View™—helping brands and retailers understand what consumers buy, why they buy it, and what to do next.
For more information, please visit www.niq.com.
NIQ-GENERAL
© 2026 Nielsen Consumer LLC. All Rights Reserved.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260527348264/en/
Contacts
Media Contact:
NIQ:media.relations@niq.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press Release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press Release
Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integration, Black Recon allows crews to launch, operate, recover, and recharge up to three unmanned aerial systems without leaving their platform, reducing risk and accelerating decision-making. “Black Recon
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press Release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press Release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press Release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom